IM Cannabis Corp is a Canada-based international medical cannabis company... Show more
The RSI Indicator for IMCC moved out of oversold territory on November 10, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In of the 34 cases the stock moved higher. This puts the odds of a move higher at .
The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on IMCC as a result. In of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for IMCC just turned positive on November 11, 2025. Looking at past instances where IMCC's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where IMCC advanced for three days, in of 203 cases, the price rose further within the following month. The odds of a continued upward trend are .
IMCC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 64 cases where IMCC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMCC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.735) is normal, around the industry mean (18.827). P/E Ratio (0.000) is within average values for comparable stocks, (71.764). IMCC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.856). IMCC has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.031). P/S Ratio (0.101) is also within normal values, averaging (39.291).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. IMCC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMCC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.
Industry PharmaceuticalsGeneric
A.I.dvisor tells us that IMCC and CRON have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMCC and CRON's prices will move in lockstep.
| Ticker / NAME | Correlation To IMCC | 1D Price Change % | ||
|---|---|---|---|---|
| IMCC | 100% | -2.04% | ||
| CRON - IMCC | 25% Poorly correlated | +0.79% | ||
| SHIEF - IMCC | 25% Poorly correlated | -28.31% | ||
| DVAX - IMCC | 23% Poorly correlated | -0.09% | ||
| SNDL - IMCC | 22% Poorly correlated | -3.24% | ||
| SCYX - IMCC | 22% Poorly correlated | -1.70% | ||
More | ||||
| Ticker / NAME | Correlation To IMCC | 1D Price Change % |
|---|---|---|
| IMCC | 100% | -2.04% |
| Pharmaceuticals: Generic industry (214 stocks) | 6% Poorly correlated | -1.00% |